reports
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Regeneron Pharmaceuticals, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 24 September 2024 in which we reassessed the appropriateness of the ratings...
Moody's upgrades Regeneron to Baa1; outlook stable
Moody's Investors Service ("Moody's") upgraded the issuer rating and the senior unsecured notes ratings of Regeneron Pharmaceuticals, Inc. ("Regeneron") to Baa1 from Baa2. At the same time, Moody's revised Regeneron's outlook to stable from positive. The ratings upgrade reflects strong operating p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.